Press Releases Year None2020201920182017201620152014 August 10, 2020 Castle Biosciences Announces Second Quarter 2020 Results August 5, 2020 Castle Biosciences to Present at the Canaccord Genuity 40th Annual Growth Conference July 27, 2020 Castle Biosciences to Release Second Quarter 2020 Financial Results and Host Conference Call on Monday, August 10, 2020 July 15, 2020 Castle Biosciences Announces Publication of Clinical Utility, Long-Term Outcomes Data and Meta-Analysis for DecisionDx-UM for Patients with Uveal Melanoma July 9, 2020 Second Systematic Review and Meta-Analysis Published Demonstrating DecisionDx-Melanoma as Independent Predictor of Recurrence, Distant Metastasis and Overall Survival in Cutaneous Melanoma July 2, 2020 Castle Biosciences Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares of Common Stock June 24, 2020 Castle Biosciences Announces Pricing of $74.0 Million Public Offering of Common Stock June 22, 2020 Castle Biosciences Announces Proposed Underwritten Public Offering of Common Stock May 22, 2020 Castle Biosciences Announces Change of Location of Annual Meeting of Stockholders to Be Held June 4, 2020 May 19, 2020 New Data Demonstrates Significant and Risk-Appropriate Clinical Impact of DecisionDx-SCC Test Results on Patient Management Decisions May 11, 2020 Castle Biosciences Announces First Quarter 2020 Results May 5, 2020 Castle Biosciences Announces Publication of a Study Evaluating Incorporation of DecisionDx-SCC into Management of High-Risk Cutaneous Squamous Cell Carcinoma April 29, 2020 Castle Biosciences Announces Publication of Validation Study for DecisionDx-SCC, Showing this Test is an Independent Predictor of Metastatic Risk in Squamous Cell Carcinoma April 27, 2020 Castle Biosciences to Release First Quarter 2020 Financial Results and Host Conference Call on Monday, May 11, 2020 April 6, 2020 Castle Biosciences to Present at the 19th Annual Needham Virtual Healthcare Conference April 2, 2020 Castle Biosciences Appoints Miles Harrison to Board of Directors April 1, 2020 Castle Biosciences Announces Publication of a Systematic Review and Meta-Analysis Demonstrating DecisionDx-Melanoma Test as Independent, Significant Predictor of Recurrence and Metastatic Risk March 27, 2020 Castle Biosciences Posts Results of Collaborative Ocular Oncology Group Survey on the Management of Ocular Oncology Patients During the COVID-19 Pandemic March 26, 2020 Castle Biosciences Announces Publication of Fourth Study Demonstrating Significant Impact of DecisionDx-UM on Treatment Plan Recommendations for Patients with Uveal Melanoma March 10, 2020 Castle Biosciences Announces Fourth Quarter and Full-Year 2019 Results March 5, 2020 Castle Biosciences Announces Issuance of First U.S. Patent Covering DecisionDx-Melanoma February 25, 2020 Castle Biosciences to Release Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on Tuesday, March 10, 2020 February 12, 2020 Castle Biosciences to Present at the 9th Annual SVB Leerink Global Healthcare Conference January 20, 2020 Castle Biosciences Announces Study Establishing the Value of Integrating DecisionDx-SCC Test into Management of High-Risk Cutaneous Squamous Cell Carcinoma January 9, 2020 Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2019 Performance Results, Delivering 29% DecisionDx-Melanoma Test Report Volume Growth in 2019
Press Releases Year None2020201920182017201620152014 August 10, 2020 Castle Biosciences Announces Second Quarter 2020 Results August 5, 2020 Castle Biosciences to Present at the Canaccord Genuity 40th Annual Growth Conference July 27, 2020 Castle Biosciences to Release Second Quarter 2020 Financial Results and Host Conference Call on Monday, August 10, 2020 July 15, 2020 Castle Biosciences Announces Publication of Clinical Utility, Long-Term Outcomes Data and Meta-Analysis for DecisionDx-UM for Patients with Uveal Melanoma July 9, 2020 Second Systematic Review and Meta-Analysis Published Demonstrating DecisionDx-Melanoma as Independent Predictor of Recurrence, Distant Metastasis and Overall Survival in Cutaneous Melanoma July 2, 2020 Castle Biosciences Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares of Common Stock June 24, 2020 Castle Biosciences Announces Pricing of $74.0 Million Public Offering of Common Stock June 22, 2020 Castle Biosciences Announces Proposed Underwritten Public Offering of Common Stock May 22, 2020 Castle Biosciences Announces Change of Location of Annual Meeting of Stockholders to Be Held June 4, 2020 May 19, 2020 New Data Demonstrates Significant and Risk-Appropriate Clinical Impact of DecisionDx-SCC Test Results on Patient Management Decisions May 11, 2020 Castle Biosciences Announces First Quarter 2020 Results May 5, 2020 Castle Biosciences Announces Publication of a Study Evaluating Incorporation of DecisionDx-SCC into Management of High-Risk Cutaneous Squamous Cell Carcinoma April 29, 2020 Castle Biosciences Announces Publication of Validation Study for DecisionDx-SCC, Showing this Test is an Independent Predictor of Metastatic Risk in Squamous Cell Carcinoma April 27, 2020 Castle Biosciences to Release First Quarter 2020 Financial Results and Host Conference Call on Monday, May 11, 2020 April 6, 2020 Castle Biosciences to Present at the 19th Annual Needham Virtual Healthcare Conference April 2, 2020 Castle Biosciences Appoints Miles Harrison to Board of Directors April 1, 2020 Castle Biosciences Announces Publication of a Systematic Review and Meta-Analysis Demonstrating DecisionDx-Melanoma Test as Independent, Significant Predictor of Recurrence and Metastatic Risk March 27, 2020 Castle Biosciences Posts Results of Collaborative Ocular Oncology Group Survey on the Management of Ocular Oncology Patients During the COVID-19 Pandemic March 26, 2020 Castle Biosciences Announces Publication of Fourth Study Demonstrating Significant Impact of DecisionDx-UM on Treatment Plan Recommendations for Patients with Uveal Melanoma March 10, 2020 Castle Biosciences Announces Fourth Quarter and Full-Year 2019 Results March 5, 2020 Castle Biosciences Announces Issuance of First U.S. Patent Covering DecisionDx-Melanoma February 25, 2020 Castle Biosciences to Release Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on Tuesday, March 10, 2020 February 12, 2020 Castle Biosciences to Present at the 9th Annual SVB Leerink Global Healthcare Conference January 20, 2020 Castle Biosciences Announces Study Establishing the Value of Integrating DecisionDx-SCC Test into Management of High-Risk Cutaneous Squamous Cell Carcinoma January 9, 2020 Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2019 Performance Results, Delivering 29% DecisionDx-Melanoma Test Report Volume Growth in 2019
July 27, 2020 Castle Biosciences to Release Second Quarter 2020 Financial Results and Host Conference Call on Monday, August 10, 2020
July 15, 2020 Castle Biosciences Announces Publication of Clinical Utility, Long-Term Outcomes Data and Meta-Analysis for DecisionDx-UM for Patients with Uveal Melanoma
July 9, 2020 Second Systematic Review and Meta-Analysis Published Demonstrating DecisionDx-Melanoma as Independent Predictor of Recurrence, Distant Metastasis and Overall Survival in Cutaneous Melanoma
July 2, 2020 Castle Biosciences Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares of Common Stock
May 22, 2020 Castle Biosciences Announces Change of Location of Annual Meeting of Stockholders to Be Held June 4, 2020
May 19, 2020 New Data Demonstrates Significant and Risk-Appropriate Clinical Impact of DecisionDx-SCC Test Results on Patient Management Decisions
May 5, 2020 Castle Biosciences Announces Publication of a Study Evaluating Incorporation of DecisionDx-SCC into Management of High-Risk Cutaneous Squamous Cell Carcinoma
April 29, 2020 Castle Biosciences Announces Publication of Validation Study for DecisionDx-SCC, Showing this Test is an Independent Predictor of Metastatic Risk in Squamous Cell Carcinoma
April 27, 2020 Castle Biosciences to Release First Quarter 2020 Financial Results and Host Conference Call on Monday, May 11, 2020
April 1, 2020 Castle Biosciences Announces Publication of a Systematic Review and Meta-Analysis Demonstrating DecisionDx-Melanoma Test as Independent, Significant Predictor of Recurrence and Metastatic Risk
March 27, 2020 Castle Biosciences Posts Results of Collaborative Ocular Oncology Group Survey on the Management of Ocular Oncology Patients During the COVID-19 Pandemic
March 26, 2020 Castle Biosciences Announces Publication of Fourth Study Demonstrating Significant Impact of DecisionDx-UM on Treatment Plan Recommendations for Patients with Uveal Melanoma
March 5, 2020 Castle Biosciences Announces Issuance of First U.S. Patent Covering DecisionDx-Melanoma
February 25, 2020 Castle Biosciences to Release Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on Tuesday, March 10, 2020
February 12, 2020 Castle Biosciences to Present at the 9th Annual SVB Leerink Global Healthcare Conference
January 20, 2020 Castle Biosciences Announces Study Establishing the Value of Integrating DecisionDx-SCC Test into Management of High-Risk Cutaneous Squamous Cell Carcinoma
January 9, 2020 Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2019 Performance Results, Delivering 29% DecisionDx-Melanoma Test Report Volume Growth in 2019
